Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before starting any prescription medication.
If you've been paying attention to weight loss over the past few years, you know Ozempic. But tirzepatide has entered the conversation in a real way. The 2025 SURMOUNT-5 trial published in the New England Journal of Medicine offered the first head-to-head clinical comparison between the two, and the results gave clinicians a clearer picture of where each drug stands.
What Is Ozempic and Why Is Everyone Talking About It?
Ozempic® is a brand name for semaglutide at doses up to 2 mg, manufactured by Novo Nordisk. It is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Ozempic® is not FDA-approved for weight loss. When used for weight management, it is prescribed off-label — meaning a licensed provider is using the medication for a purpose beyond its official approval. This is legal and common in clinical practice, but it's a distinction worth understanding.
The active ingredient in Ozempic® (semaglutide) is also the active ingredient in Wegovy®, which is FDA-approved specifically for chronic weight management at a higher dose of 2.4 mg per week.
What Is Tirzepatide and How Does It Work?
Tirzepatide is the active ingredient in Mounjaro® (approved for type 2 diabetes) and Zepbound® (approved for chronic weight management). Unlike semaglutide, which targets a single receptor, tirzepatide activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
By activating both GIP and GLP-1 receptors simultaneously, tirzepatide influences appetite, satiety, and metabolic function through two complementary hormonal pathways. This dual mechanism is why tirzepatide is pharmacologically distinct from semaglutide. It's not just a newer version — it operates differently at a biological level.
How Much Weight Can You Lose on Each?
Both medications produce meaningful weight loss. In head-to-head data, tirzepatide has the edge.
In the STEP-1 trial, participants taking semaglutide 2.4 mg (Wegovy®) lost an average of 14.9% of body weight over 68 weeks, with over 86% losing at least 5% of their body weight. (Source: NEJM, 2021)
In the SURMOUNT-1 trial, participants taking tirzepatide lost between 16% and 22.5% of body weight over 72 weeks depending on dose. (Source: Eli Lilly / NEJM, 2022)
In the 2025 SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine, tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide over 72 weeks. In absolute terms, tirzepatide users lost an average of 50.3 lbs compared to 33.1 lbs with semaglutide*. *These are averages under controlled clinical trial conditions and do not predict individual results
These are averages across clinical trial populations. Individual results vary based on biology, dose, adherence, and health history. Neither number is a guarantee.
Side Effects Compared
The side effect profiles overlap significantly. The most common side effects for both include nausea, diarrhea, vomiting, constipation, and abdominal pain, most likely during dose escalation and typically decreasing over time.
Tirzepatide has additionally noted hair loss and injection site reactions. In SURMOUNT-5, GI adverse events leading to discontinuation were slightly more common with semaglutide (5.6%) than tirzepatide (2.7%). Both carry a Boxed Warning regarding potential thyroid C-cell tumor risk observed in rodent studies. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
Compounded vs. Brand-Name: What You Should Know
Brand-name GLP-1 medications are FDA-approved at specific doses and indications, manufactured under FDA oversight. Compounded versions may contain the same active ingredient and are prepared by licensed compounding pharmacies regulated at the state level. Compounded medications are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality.
Compounded medications may be prescribed when an FDA-approved option is not medically appropriate, as determined by a licensed provider.
KINSYN offers compounded tirzepatide (kinsyn.com/weight-management/product/tirzepatide) including a tirzepatide microdose option (kinsyn.com/weight-management/product/tirzepatide-microdose), as well as compounded semaglutide (kinsyn.com/weight-management/product/compounded-semaglutide). The appropriate medication path is determined by a licensed provider who reviews your complete medical history through KINSYN's medical aggregator before making any recommendation.
*Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.*
How KINSYN Takes the Guesswork Out of the Decision
The question isn’t really “which drug is better.” The question is which drug is better for you — and that requires more than a quiz.
KINSYN is a women’s health platform built around personalized, data-driven care. Before your provider recommends anything, KINSYN’s medical aggregator integrates a significant portion of your available medical records. Digitized medical records from participating facilities — your labs, imaging, hormones, wearables, and lifestyle data — and synthesizes it into a complete health profile. Your licensed provider sees the full picture of your health before they write a single word of a prescription.
That matters when you’re choosing between two medications that work differently at a biological level. Tirzepatide’s dual mechanism may be particularly relevant for patients with certain metabolic markers. Semaglutide’s longer track record may give providers more clinical context for specific health profiles. The difference in what’s right for you might be hiding in your medical history — and KINSYN’s platform is built to surface it.
Your KINSYN membership (a $99 value) comes free with any RX purchase — no separate monthly fee. It includes 24/7 unlimited provider messaging, wearable integration for real-time health tracking, discounted biomarker lab testing, and AI-powered personalized recommendations built from your complete health profile, not a population average.
As your body responds to treatment, your plan evolves. KINSYN’s licensed providers adjust your protocol in real time with full visibility into what’s actually changing — not just what you reported at intake. This is what it looks like when weight loss treatment is built around you.
See if you’re eligible: kinsyn.com/quiz/weight-management
The Bottom Line
Tirzepatide has demonstrated stronger average weight loss results than semaglutide in clinical trials, including the first direct head-to-head comparison. Ozempic® (semaglutide) has a longer track record and has helped many people meaningfully reduce their weight.
Neither is the right choice by default. The right medication is the one that fits you — and KINSYN’s platform was built to find it.
CTA: Start your eligibility assessment at KINSYN → kinsyn.com/quiz/weight-management
Frequently Asked Questions
Is tirzepatide the same as Ozempic?
No. Tirzepatide and semaglutide (the active ingredient in Ozempic®) are different drugs with different mechanisms. Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors, which is why it is described as a dual agonist. They produce similar types of results but through different biological pathways.
Which is better for weight loss: tirzepatide or semaglutide?
In clinical trials, tirzepatide has produced higher average weight loss. The 2025 SURMOUNT-5 trial found tirzepatide achieved 20.2% body weight reduction versus 13.7% with semaglutide over 72 weeks. Individual results depend on health history, dose, and other factors. A licensed provider is best positioned to recommend the right option for you.
Is compounded tirzepatide safe?
Compounded tirzepatide uses the same active ingredient as Zepbound® and Mounjaro®, prepared by licensed compounding pharmacies regulated at the state level. Compounded medications are not FDA-approved and have not undergone FDA review for safety, efficacy, or quality. Compounded medications may be prescribed when an FDA-approved option is not medically appropriate, as determined by a licensed provider.
Can I get tirzepatide without a brand-name prescription?
Compounded tirzepatide is available through platforms like KINSYN that work with licensed compounding pharmacies. It uses the same active ingredient as brand-name tirzepatide and may be prescribed by a licensed provider after a full health evaluation, when an FDA-approved option is not medically appropriate.
What is the difference between Zepbound and Ozempic?
Zepbound® contains tirzepatide and is FDA-approved for chronic weight management. Ozempic® contains semaglutide and is FDA-approved for type 2 diabetes, used off-label for weight loss. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 only. Both are once-weekly injections.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. KINSYN is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.